Renal failure secondary to acute tubular necrosis: Epidemiology, diagnosis, and management

Chest

Volumn 128, Issue 4, 2005, Pages 2847-2863

  Gill, Namita ^a   Natty Jr , Joseph V ^a   Fatica, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Dialysis; Nephrology; Renal failure

Indexed keywords

ANTIOXIDANT; ATRIAL NATRIURETIC FACTOR; CISPLATIN; CREATININE; CYCLOSPORIN; DIURETIC AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR; FENOLDOPAM; FUROSEMIDE; GROWTH FACTOR; HORMONE; MANNITOL; PENTOXIFYLLINE; SCATTER FACTOR; SCAVENGER; SOMATOMEDIN C; THYROXINE; TRANSFORMING GROWTH FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ARTIFICIAL KIDNEY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEATH; DISEASE COURSE; ELECTROLYTE URINE LEVEL; HEMODIALYSIS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LUNG EDEMA; MORTALITY; NEPHROLOGY; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UREA NITROGEN BLOOD LEVEL;

EID: 27144462220     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2847     Document Type: Article

References (245)

1. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334:1448-1460
2. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352-357
3. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416-1420
4. Kaufman J, Dhakal M, Patel B, et al. Community acquired ARF. Am J Kidney Dis 1991; 17:191-198
5. Shusterman N, Strom BL, Murray TG, et al. Risk factors and outcomes of hospital acquired ARF: clinical epidemiologic study. Am J Med 1987; 83:65-71
6. Shankel SW, Johnson DC, Clark PS. ARF and glomerulopathy caused by NSAIDS. Arch Intern Med 1992; 152:986-990
7. Liano F, Pascual J. Epidemiology of ARF, a prospective, multi-center, community-based study: Madrid ARF Study Group. Kidney Int 1996; 50:811-818
8. Liano F, Junco E, Pascual J, et al. The spectrum of acute renal failure in the ICU compared with that seen in other settings: The Madrid Acute Renal Failure Study Group. Kidney Int 1998; 66:S16-S24
9. Corwin HL, Teplick RS, Schreiber MJ, et al. Prediction of outcome in ARF. Am J Nephrol 1987; 7:8-12
10. Davidman M, Olson P, Kohen J, et al. Iatrogenic renal disease. Arch Intern Med 1991; 151:1809-1812
11. Brivet FG, Kleinknecht DJ, Loirat P, Landrais PJ. ARF in the ICU's; causes, outcome and prognostic factors of hospital mortality; a prospective, multicenter study; French Study Group on ARF. Crit Care Med 1996; 24:192-198
12. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003; 112:460-467
13. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273:117-123
14. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351:159-169
15. De Vriese AS. Prevention and treatment of acute renal failure in sepsis. J Am Soc Nephrol 2003; 14:792-805
16. Khan RZ, Badr KF. Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant 1999; 14:814-818
17. Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830-838
18. Moran SM, Myers BD. Course of ARF studied by a model of creatinine kinetics. Kidney Int 1985; 21:928-937
19. Anderson R, Schrier RW. ARF in: Schrier RW, ed. Diseases of the kidney and urinary tract. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001
20. Corwin HL, Schreiber MJ, Fang LS. Low fractional excretion of sodium. Occurrence with hemoglobinuria and myglobiuria induced ARF. Arch Intern Med 1984; 144:981-982
21. Fang LS, Sirota RA, Ebert TH, et al. Low fractional excretion of sodium with contrast media induced ARF. Arch Intern Med 1980; 140:531-533
22. Zarich S, Fang LS, Diamond TR, et al. Fractional excretion of sodium: exceptions to its diagnostic value. Arch Intern Med 1985; 145:108-112
23. Vaz AJ. Low fractional excretion of urine sodium in acute renal failure due to sepsis. Arch Intern Med 1983; 143:738-739
24. Esson ML, Schrier RW. Diagnosis and treatment of ATN. Ann Intern Med 2002; 379:744-752
25. Solez K, Morel-Maroger L, Sraer JD. The morphology of "acute tubular necrosis" in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58:362-376
26. Wilson DM, Turner DR, Cameron JS, et al. Value of renal biopsy in acute intrinsic renal failure. BMJ 1976; 2:459-461
27. Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9:1255-1259
28. Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation 1997; 95:878-884
29. Halstenberg WK, Goormastic M, Paganini EP, et al. Utility of a risk model for renal failure in critically ill patients. Semin Nephrol 1994; 14:23-32
30. Chertow GM, Christiansen CL, Cleary PD. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 1995; 155:1505-1511
31. Neveu H, Kleinknecht D, Brivet F, et al. Prognostic factors in acute renal failure dueto sepsis. Results of a prospective multi centre study: The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 1996; 11:293-299
32. Chertow GM, Lazarus JM, Paganini EP, et al. Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis: The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 1998; 9:692-698
33. Knaus WA, Zimmerman JE, Wagner DP, et al. APACHE-Acute Physiology and Chronic Health Evaluation: a physiologically based classification system. Crit Care Med 1981; 9:591-597
34. Le Gall J, Loirat P, Alperovith A, et al. A simplified acute physiology score for ICU patients. Crit Care Med 1984; 12:975-977
35. Lemeshow S, Teres D, Pastides H, et al. A method for predicting survival and mortality of ICU patients using objectively derived weights. Crit Care Med 1985; 13:519-525
36. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829
37. Knaus W, Wagner D, Draper E, at al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized patients. Chest 1991; 100:1619-1636
38. Le Gall J, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-2963
39. Lemeshow S, Teres D, Klar J, et al. Mortality probability models (MPM II) based on an international cohort of intensive care patients. JAMA 1993; 270:2478-2486
40. Barie PS, Hydo LJ, Fisher E. Comparison of APACHE II and III scoring systems for mortality prediction in critical surgical illness. Arch Surg 1995; 130:77-82
41. Brown MC, Crede WB. Predictive ability of APACHE II scoring applied to human immunodeficiency virus positive patients. Crit Care Med 1995; 23:848-853
42. Liano F, Gallego A, Pascual J, et al. Prognosis of ATN: an extended prospectively contrasted study. Nephron 1993; 63:21-31
43. Paganini EP, Halstenberg WK, Goormastic M. Risk modelling in ARF requiring dialysis: the introduction of a new model. Clin Nephrol 1996; 46:206-211
44. Douma CE, Redekop WK, Van Den Meulen JHP, et al. Predicting mortality in ICU patients with ARF treated with dialysis. J Am Soc Nephrol 1997; 8:111-117
45. Levy EM, Viscoli CM, Horwitz RI. True effect of ARF on mortality: a cohort analysis. JAMA 1996; 275:1489-1494
46. Star RA. Treatment of ARF. Kidney Int 1998; 54:1817-1831
47. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial; the Iohexol Cooperative Study. Kidney Int 1995; 47:254-261
48. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material induced renal failure in patients with diabetis mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989; 320:143-149
49. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol 1991; 157:49-58
50. Spirazzi A, Pozzi Mucelli R. Administration of iodinated contrast in patients with pre-existing renal failure. Radiol Med (Torino) 2004; 107:88-97
51. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990; 150:1237-1242
52. Louis BM, Hoch BS, Hernandez C, et al. Protection from the nephrotoxicity of contrast dye. Ren Fail 1996; 18:639-646
53. Cigarroa RG, Lange RA, Williams RH, at al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86:649-652
54. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328-2334
55. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiocontrast-contrast agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180-184
56. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy; randomized comparison of 2 hydration regimes in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-336
57. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not prevent renal dysfunction from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003; 58:336-341
58. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62:2202-2207
59. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast associated nephrotoxicity. J Am Coll Cardiol 2002; 40:298-303
60. Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radio-contrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60:176-182
61. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111:629-638
62. Harbath S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528-534
63. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericine B nephrotoxicity. Kidney Int 1991; 40:302-308
64. Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B mediated tubular toxicity: assessment of selected cytoprotective agents. Kidney Int 1992; 41:1588-1594
65. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997; 17:27-33
66. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900-911
67. Zager RA. Gentamicin effects on renal ischemia/reperfusion injury. Circ Res 1992; 70:20-28
68. Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Curr Opin Crit Care 2001; 7:401-408
69. Hatal R, Dinh T, Cook DJ. Once daily aminoglycoside dosing in immunocompetent adults: a meta analysis. Ann Intern Med 1996; 124:717-725
70. Zager RA. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis associated acute renal failure. Am J Kidney Dis 1992; 20:223-230
71. Cabrera J, Arroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity is cirrhosis. Gastroenterology 1982; 82:97-105
72. Aronson JK, Reynolds DJM. ABC of monitoring drug therapy: aminoglycoside antibiotics. BMJ 1992; 305:1421-1424
73. Solez K, Morel-Maoger L, Sraer JD. The morphology of ATN in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58:362-376
74. Ronco C, Bellomo R. Prevention of acute renal failure in the critically ill. Nephron Clin Pract 2003; 93:C13-C20
75. Adams PL, Adams FF, Bell PD. Impaired renal blood flow autoregulation in ischemic ARF. Kidney Int 1980; 18:68-76
76. Conger JD, Robinette JB, Schrier RW. Smooth muscle calcium and endothelium-derived relaxing factor in the abnormal vascular responses of ARF. J Clin Invest 1988; 82:532-537
77. Kelleher SP, Robinette JB, Conger JD. Sympathetic nervous system in the loss of autoregulation in ARF. Am J Physiol 1984; 246:F379-F386
78. Treggiari MM, Romand JA, Burgener D, et al. Effect of increasing norepinephrine dosage on regional blood flow in a porcine model of endotoxin shock. Crit Care Med 2002; 30:1334-1339
79. LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000; 28:2729-2732
80. De Backer D, Vincent JL. Norepinephrine administration in septic shock: how much is enough? Crit Care Med 2002; 30:1398-1399
81. Lee RW, Di Giantomasso D, May C, et al. Vasoactive drugs and the kidney. Best Pract Res Clin Anaesthesiol 2004; 18:53-74
82. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717-1722
83. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal oriented hemodynamic therapy in critically ill patients: SvO2 Collaborative Group. N Engl J Med 1995; 333:1025-1032
84. Hayland DK, Cook DJ, Kind D, et al. Maximizing oxygen delivery in critically ill patients: a methodological appraisal of the evidence. Crit Care Med 1996; 24:517-524
85. Hebert PC, Wells G, Blajchman, et al. A multicenter, randomized, controlled clinical trial of tansfusion requirements in critical care: Transfusion Requirement in Critical Care Investigators; Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417
86. Flaunchbaum L, Choban PS, Dasta JF. Quantitative effects of low dose dopamine on urine output in oliguric surgical ICU patients. Crit Care Med 1994; 22:61-65
87. Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low dose dopamine or low dose dobutamine? Crit Care Med 1994; 22:1919-1925
88. Schwartz LB, Gewertz BL. The renal response to low dose dopamine. J Surg Res 1988; 45:574-588
89. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83:260-263, A5
90. Chertow GM, Sayegh MH, Allgren RL, et al. Is the administration of dopamine associated with adverse or favourable outcomes in ARF? Auriculin Anaritide ARF Study Group. Am J Med 1996; 101:49-53
91. Denton MD, Chertow GM, Brady HR. "Renal dose" dopamine for the treatment of ARF: scientific, rationale, experimental studies and clinical trials. Kidney Int 1996; 50:4-14
92. Lassnigg A, Donnor E, Grubhofer G, et al. Lack of reno-protective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11:97-104
93. Bellomo R, Chapman M, Finfer S, et al. Low dose dopamine in patients with early renal dysfunction: a placebo controlled randomized trial: Australian and New Zealand Intensive Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-2143
94. Woo EB, Tang AT, el-Gamel A, et al. Dopamine therapy for patients at risk of renal dysfunction following cardiac surgery: science or fiction? Eur J Cardiothorac Surg 2002; 22:106-111
95. Myles PS, Buckland MR, Schenk NJ, et al. Effect of "renal dose" dopamine on renal function following cardiac surgery. Anaesth Intensive Care 1993; 21:56-61
96. Wagner K, Daul A. Prevention of ARF. Med Klin 1993; 88:251-255
97. Baldwin L, Henderson A, Hickman P. Effect of post-operative low dose dopamine on renal function after elective major vascular surgery. Ann Intern Med 1994; 120:744-747
98. Power DA, Duggan J, Brady HR. Renal-dose (low-close) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Clin Exp Pharmacol Physiol Suppl 1999; 26:S23-S28
99. Lee RW, Di Giantomasso D, May C, et al. Vasoactive drugs and the kidney: best practice and research. Best Pract Res Clin Anaesthesiol 2004; 18:53-74
100. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor aginist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27:1832-1837
101. Singer I, Epstein M. Potential of dopamine A1 agonists in the management of acute renal failure. Am J Kidney Dis 1998; 31:743-755
102. Halpenny M, Markos F, Now HM, et al. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular fuction during acute hypovolemia in anesthetized dogs. Crit Care Med 2001; 29:855-860
103. Tumlin JA, Wang A, Murray PT, et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusions: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143:894-903
104. Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contract nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002; 89:999-1002
105. Kini AS, Mitre CA, Kim M, et al. A protocol for prevention of radiocontrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002; 55:169-173
106. Garwood S, Swamidass CP, Davis EA, et al. Case series of low dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J Cardiothorac Vasc Anesth 2003; 17:17-21
107. Halpenny M, Lakshmi S, O'Donell A, et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001; 56:953-960
108. Gilbert TM, Hasnain JU, Flinn WR, et al. Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J Cardiovasc Pharmacol Ther 2001; 6:31-36
109. Kellum JA. Use of diuretics in the acute care setting. Kidney Int 1998; 66:S67-S70
110. Liano F, Garcia-Martin F, Gallego A, et al. Easy and early prognosis in ATN: a forward analysis of 228 cases. Nephron 1989; 51:307-315
111. Lieberthal W, Levnisky NG. Treatment of acute tubular necrosis. Semin Nephrol 1990; 10:571-583
112. Corwin HL, Bonventre JV. Acute renal failure. Med Clin North Am 1986; 70:1037-1054
113. Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant 1997; 12:2592-2596
114. Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and non recovery of renal function in acute renal failure. JAMA 2002; 288:2547-2553
115. Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669-1677
116. Star RA. Ototoxicity in diuretic agents. In: Seldin DW, Giebisch G, eds. Clinical physiology and pharmacology. New York, NY: Academic Press, 1997; 637
117. Mason J, Joeris B, Welsch J, et al. Vascular congestion in ischemic renal failure: the role of cell swelling. Miner Electrolyte Metab 1989; 15:114-124
118. Mohaupt M, Kramer HJ. Acute ischemic renal failure: review of experimental studies and potential protective interventions. Ren Fail 1989-90; 11:177-185
119. Shillliday I, Allison ME. Diuretics in ARF. Ren Fail 1994; 16:3-17
120. Bonventre JV, Weinberg JM. Kidney preservation ex vivo for renal transplantation. Annu Rev Med 1992; 43:523-553
121. Better OS, Rubinstein I, Winaver JM, et al. Mannitol therapy revisited (1940-1997). Kidney Int 1997; 52:886-894
122. de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28:89-94
123. Yamaji T, Ishibashi M, takaku F. Atrial natriuretic factor in human blood. J Clin Invest 1985; 76:1705-1709
124. Roy DR. Effect of synthetic ANP on renal and loop of henle functions in the young rat. Am J Physiol 1986; 251:F220-F225
125. Huang CL, Lewicki J, Johnson LK, et al. Renal mechanism of action of rat ANR. J Clin Invest 1985; 75:769-773
126. Veldkamp PJ, Carmines PK, Insche EW, et al. Direct evaluation of the microascular actions of ANP in juxtamedullary nephrons. Am J Physiol 1988; 254:F440-F444
127. Shaw SG, Weidman P, Hodler J, et al. Atrial natriuretic factor peptide protects against acute ischemic renal failure. J Clin Invest 1987; 82:1232-1237
128. Rahman SN, Kim GE, Mathew AS, et al. Effects of ANP in clinical ARF. Kidney Int 1994; 45:1731-1738
129. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in ATN: Auriculin Anaritide ARF Study Group. N Engl J Med 1997; 336:828-834
130. Lewis J, Salem MM, Chertow GM, et al. ANP is oliguric ARD: Anaritide ARF Study Group. Am J Kidney Dis 2000; 36:767-774
131. Bascallao R, Fine LG. Molecular events in the organization of renal tubular epithelium: from nephrogenesis to regeneration. Am J Physiol 1989; 257:F913-F924
132. Toback FG. Regeneration after ATN. Kidney Int 1992; 41:226-246
133. Fine LG, Norman JL. Renal growth response to acute and chronic injury: routes to therapeutic intervention. J Am Soc Nephrol 1992; 2:5206-5211
134. Fine LG, Hammerman MR, Abboud HE. Evolving role of growth factors in the renal response to acute and chronic disease. J Am Soc Nephrol 1992; 2:1163-1170
135. Humes HD, Cieslinski DA. Interaction between growth factors and vetinoic acid in the induction of kidney tubulogenesis in tissue culture. Exp Cell Res 1992; 201:8-15
136. Breyer MD, Redha R, Breyer JA. Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am J Physiol 1989; 259:F553-F558
137. Arnquist HJ, Ballerman BJ, King GJ. Receptors for and effect of insulin and IGF-1 in rat glomerular mesangial cells. Am J Physiol 1988; 254:C414-C416
138. Hammerman MR, Miller SB. Therapeutic use of growth factors in renal failure. J Am Soc Nephrol 1994; 5:1-11
139. Humes HD, Cieslinski DA, Coimbra TM, et al. Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in post ischemic ARF. J Clin Invest 1989; 84:1757-1761
140. Coimbra TM, Cieslinski DA, Humes HD. Epidermal growth factor enhances renal repair in mercuric chloride nephrotoxicity. Am J Physiol 1990; 259:F438-F443
141. Miller SB, Martin DR, Kissane J, et al. IGF-1 accelerates recovery from ischemic ATN in the rat. Proc Natl Acad Sci USA 1992; 89:11876-11880
142. Miller SB. IGF-1 from bench to bedside. Paper presented at: ARF in the 21st Century (sponsored by the National Institutes of Health); May 6-8, 1996; Bethesda, MD
143. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin like growth factor 1 in patients with ARF. Kidney Int 1999; 55:2423-2432
144. Acker CG, Singh AR, Flick RP, et al. A trial of thyroxine in ARF. Kidney Int 2000; 57:293-298
145. Finn WF. Prevention of ischemic injury in renal transplantation. Kidney Int 1990; 37:171-218
146. Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in acute renal failure in the rat. J Clin Invest 1984; 74:1156-1164
147. Lieberthal W, Levine JS. Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am J Physiol 1996; 271:F477-F488
148. Weight SC, Bell PR, Nicholson ML. Renal ischemia-reperfusion injury. Br J Surg 1996; 83:162-170
149. Paller MS. The cell biology of reperfusion injury in the kidney. J Investig Med 1994; 42:632-639
150. Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med 2000; 109:655-678
151. Hughes AK, Stricklett PK, Padialla E, et al. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int 1996; 49:181-189
152. Morrow JD, Roberts LJ II. The isoprostanes: current knowledge and directions for future research. Biochem Pharmacol 1996; 51:1-9
153. Tesmafarian B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994; 16:383-391
154. Rochat C, Burkhard C, Finci-Cerkez V, et al. Oxidative stress causes a protein kinase C-independent increase of paracellular permeability in an in vitro epithelial model. Am J Respir Cell Mol Biol 1993; 9:496-504
155. Wang W, Jittikanont S, Falk SA, et al. Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. Am J Physiol 2003; 284:F532-F537
156. Edelstein CL, Ling H, Schrier RW. The nature of renal cell injury. Kidney Int 1997; 51:1341-1351
157. Ueda N, Kaushal GP, Shah SV. Apoptotic mechanism in acute renal failure. Am J Med 2000; 108:403-415
158. Greene EL, Paller MS. Oxygen free radicals in acute renal failure. Miner Electrolyte Metab 1991; 12:124-132
159. Paller MS, Hedlund BE. Role of iron in postischemic renal injury in the rat. Kidney Int 1988; 34:474-480
160. Bayati A, Hellberg O, Odlind B, et al. Prevention of ischemic ARF with superoxide dismutase and sucrose. Acta Physiol Scand 1987; 130:367-372
161. Ogawa T, Mimura Y. Antioxidant effect of zinc on acute renal failure induced by ischemic-reperfusion injury in rats. Am J Nephrol 1999; 19:609-614
162. Chatterjee PK, Cuzzocrea S, Brown PAJ, et al. Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rate. Kidney Int 2000; 58:658-673
163. Kim SY, Kim CH, Yoo HJ, et al. Effects of radical scavengers and antioxidants on ischemic acute renal failure in rabbits. Ren Fail 1999; 21:1-11
164. Zager RA, Fuerstenberg SM, Baehr PH, et al. An evaluation of antioxidant effects on recovery from postischemic acute renal failure. J Am Soc Nephrol 1994; 4:1588-1597
165. Krysztopik RJ, Matheson PJ, Spain DA, et al. Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism. J Surg Res 2000; 93:75-81
166. Ambrus JL, Halpern J, Mahafzah M, et al. Platelet aggregation in septic shock: effects of pentoxifylline. J Med 1990; 21:121-128
167. Fink MP. Whither pentoxifylline? Crit Care Med 1999; 27:19-20
168. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34:50-97
169. Mandell GL. ARDS, neutrophils, and pentoxyfylline. Am Rev Respir Dis 1988; 138:1103-1105
170. Berens KL, Langston JD, Wasan KM, et al. Influence of pentoxifylline and related analogues in eudotoxemic renal failure. Circ Shock 1991; 34:344-348
171. Kim YK, Yoo JH, Woo JS, et al. Effect of pentoxifylline on ischemic acute renal failure in rabbits. Ren Fail 2001; 23:757-772
172. Kim YK, Choi TR, Kwon CH, et al. Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Ren Fail 2003; 25:909-922
173. Savic V, Vlahovic P, Djordjevic V, et al. Nephroproctective effects of pentoxifylline in experimental myoglobinuric acute renal failure. Pathol Biol (Paris) 2002; 50:599-607
174. Shifow AA, Naidu MU, Kumar KV, et al. Effect of pentoxifylline on cyclosporine-induced nephrotixicity in rats. Indian J Exp Biol 2000; 38:347-352
175. Boldt J, Muller M, Heesen M, et al. The effects of pentoxyfylline on circulating adhesion molecules in critically ill patients with ARF treated by CVVH. Intensive Care Med 1996; 22:305-311
176. Boldt J, Brosch C, Piper SN, et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med 2001; 29:952-958
177. Klouche K, Beraud JJ. Nutrition in acute renal failure. In: Cantarovich F, Rangoonvala B, Venho M, eds. Progress in ARF. Bridgewater, NJ: Euromed Communications Ltd, 1998; 195-224
178. Druml W. Nutritional support in ARF. In: Mitch WE, Klahr S, eds. Handbook of nutrition and the kidney. 3rd ed. Philadelphia, PA: Lippincott-Raven Publishers, 1998; 213-236
179. Druml W. Metabolic alterations in ARF. Contrib Nephrol 1992; 98:59-66
180. Druml W. Nutritional management of ARF. Am J Kidney Dis 2001; 37:S89-S94
181. Druml W. Protein metabolism in ARF. Miner Electrolyte Metab 1998; 24:47-54
182. Price SR, Reaich D, Marinovic AC, et al. Mechanisms contributing to muscle wasting in acute uremia: activation of amino acid catabolism. J Am Soc Nephrol 1998; 9:439-443
183. Cianciaruso B, Belizzi V, Napoli R, et al. Hepatic uptake and release of glucose, llactate, and amino acids in acutely uremic dogs. Metabolism 1991; 40:261-269
184. Druml W, Fisher M, Sertl S, et al. Fat elimination in ARF. Long chain versus medium chain triglycerides. Am J Clin Nutr 1992; 55:468-472
185. Schneeweiss B, Graninger W, Stockenhuber F, et al. Energy metabolism in acute and chronic renal failure. Am J Clin Nutr 1990; 52:596-601
186. Hayashi N, Tashir T, Yamamori H, et al. Effects of intravenous omega-3 and omega-6 fat emulsion on cytokine production and delayed type hypersensitivity in burned rats receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr 1998; 22:363-367
187. Takagi K, et al. n-3 versus n-6 polyunsaturated fatty acids in critical illness. Nutrition 1998; 14:551-553
188. Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med 1999; 27:2799-2805
189. Heyland DK, Novak F, Drover JW, et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001; 286:944-953
190. Klein CJ, Stanek GS, Wiles CE III. Overfeeding macronutrients to critically ill adults: metabolic complications. J Am Diet Assoc 1998; 98:795-806
191. Macias WL, Alaka KJ, Murphy MH, et al. Impact of nutritional regimen on protein catabolism and nitrogen balance in patients with ARF. JPEN J Parenter Enteral Nutr 1996; 20:56-62
192. Druml W. Nutritional support in ARF. In: Mitch WE, Klahr S, eds. Nutrition and the kidney. Boston, MA: Little Brown, 1998; 314-345
193. Bellomo R, Seacombe J, Daskalakis M, et al. A prospective comparative study of moderate versus high protein intake for critically ill patients with ARF. Ren Fail 1997; 19:111-120
194. Fiaccadori E, Maggiore U, Giacosa R, et al. Enteral nutrition in patients with ARF. Kidney Int 2004; 65:999-1008
195. Gottschlich MM, Jenkins M, Warden GD, et al. Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN J Parenter Enteral Nutr 1990; 14:225-236
196. Riella MC. Nutrition in ARF. Ren Fail 1997; 19:237-252
197. Roberts PR, Black KW, Zaloga GP. Enteral feeding improves outcome and protects against glycerol-incluced ARF in the rate. Am J Respir Crit Care Med 1997; 156:1265-1269
198. Heyland DK. Nutritional support in the critically ill: a critical review of the evidence. Crit Care Clin 1998; 14:423-440
199. Btaiche IF, Khalidi N. Metabolic complications of perenteral nutrition, part 1. Am J Health Syst Pharm 2004; 61:1938-1949
200. Btaiche IF, Khalidi N. Metabolic complications of perenteral nutrition, part 2. Am J Health Syst Pharm 2004; 61:2050-2057
201. Mehta RL, McDonald B, Gabbai F, et al. Nephrology consultation in acute renal failure: does timing matter? Am J Med 2002; 113:456-461
202. Teehan GS, Liangos O, Jaber BL. Update on dialytic management of ARF. J Intensive Care Med 2003; 18:130-138
203. Mehta RL, McDonald B, Gabbai F, et al. A randomized clinical trial of continuous versus intermittent dialysis for ARF. Kidney Int 2001; 60:1154-1163
204. van Bommel EF, Ponssen HH. Intermittent versus continuous treatment for ARF: where do we stand? Am J Kidney Dis 1997; 30:S72-S79
205. Kellum JA, Angus DC, Johnson LP, et al. Continuous versus intermittent renal replacement: a meta analysis. Intensive Care Med 2002; 28:29-37
206. Augustine JJ, Sandy D, Seifert TH, Paganini EP. A randomized controlled trial comparing intermittent and continuous dialysis in patients with ARF. Am J Kidney Dis 2004; 44:1000-1007
207. Conger J. Dialysis and related therapies. Semin Nephrol 1998; 18:533-540
208. Kumar VA, Yeun JY, Depner TA, et al. Extended daily dialysis vs continuous hemodialysis for ICU patients with ARF: a two-year single center report. Int J Artif Organs 2004; 27:371-379
209. Chitalia VC, Almeida AF, Rai HB, et al. Is peritoneal dialysis adequate for hypercatabolic ARF in developing countries? Kidney Int 2002; 61:747-757
210. Phu HN, Hein TT, Mai NTH, et al. Hemofiltration and peritoneal dialysis in infection associated ARF in Vietnam. N Engl J Med 2002; 347:895-902
211. Craddock PR, Fehr J, Dalmasso AP, et al. Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59:879-888
212. Hakim RM, Breilatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311:878-882
213. Schiffl H, Sitter T, Lang S, et al. Bioincompatible membranes place patients with ARF at increased risk of infections. ASAIO J 1995; 41:M709-M712
214. Himmelfarb J, Tolkoff Rubin NT, Chandran P, et al. A multicenter comparison of dialysis membranes on the treatment of ARF requiring dialysis. J Am Soc Nephrol 1998; 9:257-266
215. Kurtal H, von Herrath D, Schaefer K. Is the choice of membrane important in patients with ARF requiring hemodialysis. Artif Organs 1995; 19:391-394
216. Assouad M, Tseng S, Dunn K, et al. Biocompatibility of dialyzer membranes is important in the outcome of ARF [abstract]. J Am Soc Nephrol 1996; 7:1437
217. Jorres J, Gahl GM, Dobis C, et al. Hemodialysis membrane compatibility and mortality in patients with dialysis dependant ARF: a prospective randomized multicenter trial. Lancet 1999; 354:1337-1341
218. Gastaldello K, Melot C, Kahn R-J, et al. Comparison of cellulose diacetate and polysulfone membranes in the outcome of ARF: a prospective randomized study. Nephrol Dial Trans 2000; 15:224-230
219. Albright RC, Smelser JM, McCarthy JT. Patient survival and renal recovery in ARF: randomized comparison of cellulose acetate and polysulfone membrane dialyzers. Mayo Clin Proc 2000; 75:1141-1147
220. Jaber B, Lau J, Schmid CH, et al. Effect of biocompatibility of hemodialysis membranes on mortality in ARF: a meta analysis. Clin Nephrol 2002; 57:274-282
221. Colton CK, Henderson LW, Ford CA, et al. Kinetics of hemodiafiltration: in vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med 1975; 85:355-371
222. Sigler MH. Transport characteristics of the slow therapies: implications for achieving adequacy of dialysis in ARF. Adv Ren Replace Ther 1997; 4:68-80
223. Friedman AN, Jaber BL. Dialysis adequacy in patients with ARF. Curr Opin Nephrol Hypertens 1999; 8:695-700
224. Ponikvar JB, Rus RR, Kenda RB, et al. Low-flux versus high-flux synthetic dialysis membrane in ARF: a prospective randomized study. Artif Organs 2001; 25:946-950
225. Kleinknecht D, Jungers P, Chanard J, et al. Uremic and non uremic complications in ARF: evaluation of frequent and early dialysis on prognosis. Kidney Int 1972; 1:190-196
226. Fischer RP, Griffen WO Jr, Clark DS, et al. Postoperative renal failure. Lancet 1968; 88:42-46
227. Conger JD. A controlled evaluation of prophylactic dialysis in post-traumatic ARF. J Trauma 1975; 15:1056-1063
228. Gillum DM, Dixon BS, Yanover MJ, et al. The role of intensive dialysis in ARF. Clin Nephrol 1986; 25:249-255
229. Demirkilic U, Kuralay E, Yenicesu M, et al. Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg 2004; 19:17-20
230. Schiffl H, Lang S, Fisher R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305-310
231. Gotch S, Sargent J, A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28:526-534
232. Evanson JA, Himmelfarb J, Wingard R, et al. Prescribed versus delivered dialysis in ARF patients. Am J Kidney Dis 1998; 32:731-738
233. Paganini EP, Kanagasundaram NS, Larive B, et al. Prescription of adequate RRT in critically ill patients. Blood Purif 2001; 19:238-244
234. Ronco CBR, Homel P, Brendolan A, et al. Effects of different doses in CVVH on outcomes of ARF: a prospective randomized trial. Lancet 2000; 356:26-30
235. Storck M, Hartl WH, Zimmerer F, et al. Comparison of pump driven and spontaneous continuous hemofiltration in post operative ARF. Lancet 1991; 337:452-455
236. Rose BD. Pathophysiology of renal disease. 2nd ed. New York, NY: McGraw-Hill, 1987; 87-88
237. Myers BD, Miller DC, Mehigan JT, et al. Nature of the renal injury following total renal ischemia in man. J Clin Invest 1984; 73:329-341
238. Gornick CC Jr, Kjellstrand CM. Acute renal failure complicating aortic aneursm surgery. Nephron 1983; 35:145-157
239. Yeboah ED, Petrie A, Pead JL. ARF and open heart surgery. BMJ 1972; 1:415-418
240. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization; risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 1998; 128:194-203
241. Dawson JL. Acute post-operative renal failure in obstructive jaundice. Ann R Coll Surg Engl 1968; 42:163-181
242. Durmaz I, Yagdi T, Calkavur T, et al. Prophylactic dialysis in patients undergoing on pump coronary artery bypass surgery. Ann Thorac Surg 2003; 75:859-864
243. Humes HD, Weitzel WF, Bartkett RH, et.al. Renal cell therapy is associated with dynamic and individualized responses in patients with ARF. Blood Purif 2003; 21:64-71
244. Kishore KK, Sandy D, Paganini EP. The move from dead to living membranes: bioartificial organ support of failing systems. Adv Ren Replace Ther 1998; 5:324-332
245. Humes HD, Weitzel WE, Bartlett RH, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with ARF. Kidney Int 2004; 66:1578-1588